Traws Pharma, Inc. 8-K

What Happened

• Traws Pharma, Inc. (TRAW) filed an 8-K on May 26, 2026 updating its At-The-Market (ATM) Offering Agreement with Citizens JMP Securities, LLC. The original ATM Agreement (entered March 10, 2025) allows the company to offer and sell up to $50,000,000 of common stock (subject to limitations in the agreement).
• The company’s effective shelf registration statement (Form S-3, Reg. No. 333-273081, filed June 30, 2023; declared effective July 11, 2023) and prospectus supplements dated March 10, 2025, April 7, 2025 and May 22, 2026 limit the current immediate offering capacity to $3,128,399 under the Form S-3 “baby shelf” rule.

Key Details

• ATM sales agent: Citizens JMP Securities, LLC.
• Maximum contractual ATM capacity: up to $50,000,000 (subject to ATM Agreement limits).
• Current “baby shelf” offering limit under the prospectus supplements: $3,128,399.
• Legal opinion from Snell & Wilmer L.L.P. relating to the Shares is filed as Exhibit 5.1 to the 8-K.

Why It Matters

• The ATM program gives Traws Pharma a flexible method to raise capital by selling shares into the market over time. The immediate practical limit is $3.13M because of the Form S-3 “baby shelf” constraint.
• For investors, any future share sales under this program could dilute existing holdings and affect the share count and stock price; monitoring prospectus supplements and actual offering activity is important.
• The filing itself is procedural (an update and legal opinion) and does not report that any shares have been sold—only that the company has the ability to sell up to the stated amounts under the stated limits.